Management strategies for heparin-induced thrombocytopenia in heart-transplant candidates: case report and review of the literature.
Management of anticoagulation in patients with heparin-induced thrombocytopenia (HIT) undergoing surgery requiring cardiopulmonary bypass (CPB), such as cardiac transplantation, represents a difficult clinical problem and no clear management strategy exists. The cases of 2 patients with HIT who underwent cardiac transplantation using differing anticoagulation strategies are presented with a discussion of potential advantages and pitfalls of each approach used.
Pamboukian
S V
SV
Cardiac Transplant and Heart Failure fellow,a Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, USA.
Ignaszewski
A P
AP
Ross
H J
HJ
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D016027:Heart Transplantation; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006497:Heparan Sulfate; D014859:Warfarin; C035838:danaparoid